Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

TEGNA (TGNA) to Report Q1 Earnings: What's in the Cards?

Published 05/05/2020, 06:22 AM
Updated 07/09/2023, 06:31 AM

TEGNA (NYSE:TGNA) TGNA is set to report first-quarter 2020 results on May 7.

The Zacks Consensus Estimate for earnings currently stands at 37 cents per share, implying 27.6% growth from the figure reported in the year-ago quarter. The bottom-line estimate has been revised a penny downward over the past 30 days.

Moreover, the consensus mark for revenues is currently pegged at $683 million, indicating a 32.2% surge from the year-ago quarter’s reported figure.

Notably, the company’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and matched the mark in one, the average positive surprise being 6.52%.

TEGNA Inc. Price and EPS Surprise

TEGNA Inc. price-eps-surprise | TEGNA Inc. Quote

Let’s see how things are shaping up for this announcement.

TEGNA Reports Strong Interim Results

TEGNA reported its preliminary first-quarter 2020 results on Apr 20. Revenues are expected to be $684 million, up 32% year over year and in line with the company’s prior guidance, driven by acquisitions and steady growth in subscription revenues as well as political advertising spending. Excluding political advertising, quarterly revenues are expected to be up 24% year over year.

Non-GAAP diluted earnings are expected to be 43 cents per share, up $48 year over year. Adjusted EBITDA is expected to be $212 million, up 39% year over year, reflecting solid contributions from new as well as existing stations and benefits from the on-going cost-containment efforts.

Factors to Consider

TEGNA’s preliminary first-quarter results reflect benefits of a stable subscriber base. Moreover, the company’s acquisitions of local TV stations comprising the Big Four affiliates are likely to have aided the top line in the to-be-reported quarter.

Further, renewal of CBS and Fox affiliate agreements is expected to have boosted revenues. Apart from higher political advertising spending that might have benefited the top line, solid retransmission rates are expected to have fueled TEGNA’s growth.

Further, we believe that climbing viewership of local news and media consumption due to lockdowns and shelter-in-place guidelines bodes well for the company’s first-quarter results.

However, lower advertising spending due to the coronavirus outbreak is expected to have affected Advertising & Marketing services, which accounts for more than 55% of TEGNA’s revenues.

Additionally, increasing programming fees and investments in content and digital are expected to have weighed on margins in the to-be-reported quarter.

What Our Model Indicates

Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.

TEGNA has an Earnings ESP of -1.37% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks to Consider

Here are some companies worth considering from the sector as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:

Shopify (NYSE:SHOP) SHOP has an Earnings ESP of +23.41% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Inphi (NYSE:IPHI) Corporation IPHI has an Earnings ESP of +20.04% and is Zacks #2 Ranked.

Take Two Interactive TTWO has an Earnings ESP of +13.24% and a Zacks Rank #2.


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Take-Two (NASDAQ:TTWO) Interactive Software, Inc. (TTWO): Free Stock Analysis Report

Inphi Corporation (IPHI): Free Stock Analysis Report

TEGNA Inc. (TGNA): Free Stock Analysis Report

Shopify Inc. (SHOP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.